Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

UNCY

Unicycive Therapeutics Inc

Apr 16 • 11:28AM ET

7.00

+0.03 0.43 %

Healthcare • Biotechnology • USA • NASD

Peers: BTAI RAPT ARDX ANVS CRBP CUE LGVN CAPR CRDF

| Held by: VTI VXF DFAS DFMC DFAC DCOR DFSU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.02	Insider Own	11.26%	Shs Outstand	25.24M	Perf Week	5.26%
Market Cap	176.67M	Forward P/E	0.87	EPS next Y	8.07	Insider Trans	0.00%	Shs Float	22.40M	Perf Month	0.29%
Enterprise Value	135.60M	PEG	-	EPS next Q	-0.36	Inst Own	36.04%	Short Float	8.15%	Perf Quarter	5.90%
Income	-26.62M	P/S	-	EPS this Y	92.66%	Inst Trans	3.51%	Short Ratio	3.24	Perf Half Y	53.51%
Sales	0.00M	P/B	5.13	EPS next Y	6686.39%	ROA	-65.88%	Short Interest	1.83M	Perf YTD	21.32%
Book/sh	1.37	P/C	4.28	EPS next 5Y	-	ROE	-141.47%	52W High	11.00 -36.36%	Perf Year	17.06%
Cash/sh	1.64	P/FCF	-	EPS past 3/5Y	48.15% -2.40%	ROIC	-88.14%	52W Low	3.71 88.68%	Perf 3Y	-60.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.92% 5.78%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	80.61%	Oper. Margin	-	ATR (14)	0.39	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.59	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.92	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.59	EPS Q/Q	64.92%	SMA20	4.74%	Beta	1.75	Target Price	43.75
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	4.86%	Rel Volume	0.61	Prev Close	6.97
Employees	21	LT Debt/Eq	0.00	Earnings	Mar 30 BMO	SMA200	27.86%	Avg Volume	563.34K	Price	7.00
IPO	Jul 13, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	37.56% -	Trades		Volume	115,706	Change	0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-25	Initiated	Guggenheim	Buy	$6
Apr-04-24	Initiated	Piper Sandler	Overweight	$9

Apr-09-26 07:05AM	Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-26 07:05AM	Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-17-26 09:15AM	Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
Feb-04-26 07:05AM	Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit (GlobeNewswire) -5.92%
Jan-29-26 09:15AM	UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission (GlobeNewswire)
07:05AM	Loading…
07:05AM	Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission (GlobeNewswire)
Dec-29-25 07:05AM	Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Dec-01-25 01:41PM	Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile) -7.26%
Nov-25-25 07:05AM	Unicycive Therapeutics to Participate in Upcoming Investor Events in December (GlobeNewswire)
Nov-12-25 07:05AM	Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.31%
Nov-03-25 07:05AM	Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire) -6.53%
Oct-30-25 07:05AM	Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference (GlobeNewswire)
Oct-28-25 07:05AM	Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End (GlobeNewswire) -9.92%
Oct-14-25 09:50AM	Did You Lose Money on Unicycive Therapeutics, Inc. (UNCY)? Levi & Korsinsky Urges Investors to Act Before October 14, 2025 (Newsfile)
Oct-13-25 05:31PM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY (PR Newswire)
05:13PM	Loading…
Oct-08-25 05:13PM	Investors in Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights - Contact Levi & Korsinsky Before October 14, 2025 (Newsfile)
Oct-02-25 08:04AM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY (PR Newswire)
Sep-26-25 09:00AM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY (PR Newswire) +7.49%
Sep-25-25 03:19PM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights UNCY (Business Wire)
Aug-26-25 07:00AM	Unicycive Therapeutics to Participate in Upcoming Investor Events in September (GlobeNewswire)
Aug-22-25 08:45AM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY (PR Newswire)
Aug-21-25 07:05AM	Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately. (PR Newswire)
Aug-18-25 07:05AM	Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease (GlobeNewswire) -13.19%
Aug-14-25 07:00AM	Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-24-25 08:00AM	Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology (GlobeNewswire) +5.21%
Jul-08-25 08:30AM	Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +5.97%
Jul-07-25 07:00AM	Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference (GlobeNewswire)
Jun-30-25 07:05AM	Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -29.85%
Jun-17-25 07:00AM	Unicycive Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -8.96%
Jun-10-25 06:00AM	Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -40.88%
07:00AM	Loading…
May-22-25 07:00AM	Unicycive Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-21-25 07:00AM	Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders (GlobeNewswire) -5.00%
May-14-25 07:15AM	Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.83%
Apr-10-25 08:00AM	Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis (GlobeNewswire)
Apr-01-25 07:00AM	Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.03%
Mar-31-25 07:00AM	Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.37%
Mar-26-25 11:59AM	DaVita Stock Declines 1.2% in 3 Months: Here's How to Play (Zacks)
Mar-13-25 07:00AM	Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia (GlobeNewswire)
Feb-20-25 07:00AM	Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 (GlobeNewswire)
Jan-28-25 07:00AM	Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science (GlobeNewswire) -5.44%
Jan-07-25 07:00AM	Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science (GlobeNewswire)
Dec-17-24 07:00AM	Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics (GlobeNewswire)
Nov-21-24 07:00AM	Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 07:15AM	Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:00AM	Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -9.63%
Oct-28-24 07:03AM	Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire) +20.24%
Oct-16-24 04:35PM	Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 (GlobeNewswire) +11.39%
11:43AM	Results of Phase I trial shed positive light on UNI-494 for acute kidney injury (Clinical Trials Arena)
Oct-14-24 07:03AM	Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
Oct-11-24 07:03PM	Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc (GuruFocus.com)
Oct-09-24 07:03AM	Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers (GlobeNewswire)
Sep-24-24 07:03AM	Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) +6.98%
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
07:03AM	Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 (GlobeNewswire)
Sep-05-24 07:03AM	Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 07:03AM	Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -5.89%
Aug-26-24 07:03AM	Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
Aug-14-24 07:10AM	Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +34.03%
Jul-17-24 07:03AM	Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO) (GlobeNewswire) -6.99%
Jul-11-24 07:03AM	Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference (GlobeNewswire)
Jul-10-24 07:03AM	Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Jul-01-24 07:03AM	Unicycive Therapeutics Joins Russell Microcap Index (GlobeNewswire) +7.76%
Jun-25-24 07:30AM	Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial (GlobeNewswire) -26.76%
May-28-24 07:03AM	Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress (GlobeNewswire) -11.65%
May-23-24 07:03AM	Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference (GlobeNewswire)
May-15-24 07:03AM	Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting (GlobeNewswire)
May-13-24 10:53PM	UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:16PM	Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 07:00AM	3 Top Penny Stocks to Buy for Explosive Returns: April Edition (InvestorPlace)
Apr-29-24 01:37PM	These 2 Strong Buy Penny Stocks Could Rally to $9, Says Piper Sandler (TipRanks) +18.45%
Apr-10-24 07:03AM	Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Mar-28-24 10:53PM	UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -5.48%
04:15PM	Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-24 07:03AM	Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress (GlobeNewswire)
Mar-14-24 07:03AM	Unicycive Announces $50 Million Private Placement (GlobeNewswire)
Mar-13-24 07:03AM	Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference (GlobeNewswire)
Mar-07-24 04:12PM	Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Mar-04-24 07:03AM	Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients (GlobeNewswire) -6.88%
Feb-14-24 07:03AM	Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting (GlobeNewswire) +10.48%
Jan-29-24 07:03AM	Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference (GlobeNewswire) +7.43%
Jan-24-24 09:39AM	Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update (Zacks)
Jan-23-24 07:03AM	Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones (GlobeNewswire) +18.29%
Dec-18-23 07:03AM	Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire)
Nov-29-23 07:03AM	Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023 (GlobeNewswire) -5.37%
Nov-14-23 04:15PM	Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-23-23 07:03AM	Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC) (GlobeNewswire) -7.91%
Sep-06-23 07:03AM	Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD (GlobeNewswire)
Aug-29-23 07:03AM	Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series (GlobeNewswire)
Aug-14-23 05:36PM	Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.37%
Jul-21-23 04:30PM	CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
09:00AM	60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
Jul-20-23 07:03AM	Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference (GlobeNewswire)
Jul-18-23 07:03AM	Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology (GlobeNewswire)
Jun-29-23 05:04PM	Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program (GlobeNewswire) -22.42%
Jun-16-23 07:38AM	Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET (GlobeNewswire) -7.59%
Jun-09-23 09:00AM	Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report® (ACCESSWIRE) +12.90%
May-17-23 06:03AM	Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit Outlook (Simply Wall St.)
May-16-23 08:29AM	Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-23 07:00AM	Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress (GlobeNewswire)

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UNCY

Unicycive Therapeutics Inc

Upgrade your Finviz experience